Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Labetalol vs PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Oral: 1 tablet (propranolol 40 mg / hydrochlorothiazide 25 mg) twice daily or as needed to control blood pressure; maximum propranolol 320 mg/day.
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
None Documented
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Propranolol: 3-6 hours (terminal) with significant interindividual variability; prolonged in hepatic impairment (up to 11 hours). Hydrochlorothiazide: 6-15 hours (terminal); prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Propranolol: <1% unchanged in urine; extensively metabolized in liver, metabolites (4-hydroxypropanolol and others) excreted renally (90%) and fecally (10%). Hydrochlorothiazide: >95% renally excreted unchanged; negligible biliary/fecal elimination.
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker